Cargando…
Clinical impact of serum soluble SLAMF7 in multiple myeloma
The signaling lymphocytic activation molecule family (SLAMF7; also known as CS1 or CD319) is highly expressed on plasma cells from multiple myeloma (MM) as well as natural killer (NK) cells and is a well-known therapeutic target of elotuzumab. The objective of this study was to evaluate the clinical...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6205184/ https://www.ncbi.nlm.nih.gov/pubmed/30410677 http://dx.doi.org/10.18632/oncotarget.26196 |
_version_ | 1783366162439995392 |
---|---|
author | Ishibashi, Mariko Soeda, Saori Sasaki, Makoto Handa, Hiroshi Imai, Yoichi Tanaka, Norina Tanosaki, Sakae Ito, Shigeki Odajima, Takeshi Sugimori, Hiroki Asayama, Toshio Sunakawa, Mika Kaito, Yuta Kinoshita, Ryosuke Kuribayashi, Yasuko Onodera, Asaka Moriya, Keiichi Tanaka, Junji Tsukune, Yutaka Komatsu, Norio Inokuchi, Koiti Tamura, Hideto |
author_facet | Ishibashi, Mariko Soeda, Saori Sasaki, Makoto Handa, Hiroshi Imai, Yoichi Tanaka, Norina Tanosaki, Sakae Ito, Shigeki Odajima, Takeshi Sugimori, Hiroki Asayama, Toshio Sunakawa, Mika Kaito, Yuta Kinoshita, Ryosuke Kuribayashi, Yasuko Onodera, Asaka Moriya, Keiichi Tanaka, Junji Tsukune, Yutaka Komatsu, Norio Inokuchi, Koiti Tamura, Hideto |
author_sort | Ishibashi, Mariko |
collection | PubMed |
description | The signaling lymphocytic activation molecule family (SLAMF7; also known as CS1 or CD319) is highly expressed on plasma cells from multiple myeloma (MM) as well as natural killer (NK) cells and is a well-known therapeutic target of elotuzumab. The objective of this study was to evaluate the clinical significance of serum soluble SLAMF7 (sSLAMF7) levels in patients with MM (n=103) and furthermore the impact of sSLMF7 on the antitumor activity of anti-SLAMF7 antibody. Thirty-one percent of MM patients, but not patients with monoclonal gammopathy of undetermined significance and healthy controls, had detectable levels of serum sSLAMF7, which were significantly increased in advanced MM patients. Further, MM in sSLAMF7-postive patients exhibited aggressive clinical characteristics with shorter progression-free survival times in comparison with sSLAMF7-negative patients. In responders to MM therapy, the levels of sSLAMF7 were undetectable or decreased compared with those before treatment. In addition, the anti-SLAMF7 antibody-mediated antibody-dependent cellular cytotoxicity of NK cells against MM cell lines was inhibited by recombinant SLAMF7 protein. Thus, our findings suggest that high concentrations of sSLAMF7, which could transiently suppress the therapeutic effects of elotuzumab, may be a useful indicator of disease progression in MM patients. |
format | Online Article Text |
id | pubmed-6205184 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Impact Journals LLC |
record_format | MEDLINE/PubMed |
spelling | pubmed-62051842018-11-08 Clinical impact of serum soluble SLAMF7 in multiple myeloma Ishibashi, Mariko Soeda, Saori Sasaki, Makoto Handa, Hiroshi Imai, Yoichi Tanaka, Norina Tanosaki, Sakae Ito, Shigeki Odajima, Takeshi Sugimori, Hiroki Asayama, Toshio Sunakawa, Mika Kaito, Yuta Kinoshita, Ryosuke Kuribayashi, Yasuko Onodera, Asaka Moriya, Keiichi Tanaka, Junji Tsukune, Yutaka Komatsu, Norio Inokuchi, Koiti Tamura, Hideto Oncotarget Research Paper The signaling lymphocytic activation molecule family (SLAMF7; also known as CS1 or CD319) is highly expressed on plasma cells from multiple myeloma (MM) as well as natural killer (NK) cells and is a well-known therapeutic target of elotuzumab. The objective of this study was to evaluate the clinical significance of serum soluble SLAMF7 (sSLAMF7) levels in patients with MM (n=103) and furthermore the impact of sSLMF7 on the antitumor activity of anti-SLAMF7 antibody. Thirty-one percent of MM patients, but not patients with monoclonal gammopathy of undetermined significance and healthy controls, had detectable levels of serum sSLAMF7, which were significantly increased in advanced MM patients. Further, MM in sSLAMF7-postive patients exhibited aggressive clinical characteristics with shorter progression-free survival times in comparison with sSLAMF7-negative patients. In responders to MM therapy, the levels of sSLAMF7 were undetectable or decreased compared with those before treatment. In addition, the anti-SLAMF7 antibody-mediated antibody-dependent cellular cytotoxicity of NK cells against MM cell lines was inhibited by recombinant SLAMF7 protein. Thus, our findings suggest that high concentrations of sSLAMF7, which could transiently suppress the therapeutic effects of elotuzumab, may be a useful indicator of disease progression in MM patients. Impact Journals LLC 2018-10-05 /pmc/articles/PMC6205184/ /pubmed/30410677 http://dx.doi.org/10.18632/oncotarget.26196 Text en Copyright: © 2018 Ishibashi et al. http://creativecommons.org/licenses/by/3.0/ This article is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0/) (CC-BY), which permits unrestricted use and redistribution provided that the original author and source are credited. |
spellingShingle | Research Paper Ishibashi, Mariko Soeda, Saori Sasaki, Makoto Handa, Hiroshi Imai, Yoichi Tanaka, Norina Tanosaki, Sakae Ito, Shigeki Odajima, Takeshi Sugimori, Hiroki Asayama, Toshio Sunakawa, Mika Kaito, Yuta Kinoshita, Ryosuke Kuribayashi, Yasuko Onodera, Asaka Moriya, Keiichi Tanaka, Junji Tsukune, Yutaka Komatsu, Norio Inokuchi, Koiti Tamura, Hideto Clinical impact of serum soluble SLAMF7 in multiple myeloma |
title | Clinical impact of serum soluble SLAMF7 in multiple myeloma |
title_full | Clinical impact of serum soluble SLAMF7 in multiple myeloma |
title_fullStr | Clinical impact of serum soluble SLAMF7 in multiple myeloma |
title_full_unstemmed | Clinical impact of serum soluble SLAMF7 in multiple myeloma |
title_short | Clinical impact of serum soluble SLAMF7 in multiple myeloma |
title_sort | clinical impact of serum soluble slamf7 in multiple myeloma |
topic | Research Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6205184/ https://www.ncbi.nlm.nih.gov/pubmed/30410677 http://dx.doi.org/10.18632/oncotarget.26196 |
work_keys_str_mv | AT ishibashimariko clinicalimpactofserumsolubleslamf7inmultiplemyeloma AT soedasaori clinicalimpactofserumsolubleslamf7inmultiplemyeloma AT sasakimakoto clinicalimpactofserumsolubleslamf7inmultiplemyeloma AT handahiroshi clinicalimpactofserumsolubleslamf7inmultiplemyeloma AT imaiyoichi clinicalimpactofserumsolubleslamf7inmultiplemyeloma AT tanakanorina clinicalimpactofserumsolubleslamf7inmultiplemyeloma AT tanosakisakae clinicalimpactofserumsolubleslamf7inmultiplemyeloma AT itoshigeki clinicalimpactofserumsolubleslamf7inmultiplemyeloma AT odajimatakeshi clinicalimpactofserumsolubleslamf7inmultiplemyeloma AT sugimorihiroki clinicalimpactofserumsolubleslamf7inmultiplemyeloma AT asayamatoshio clinicalimpactofserumsolubleslamf7inmultiplemyeloma AT sunakawamika clinicalimpactofserumsolubleslamf7inmultiplemyeloma AT kaitoyuta clinicalimpactofserumsolubleslamf7inmultiplemyeloma AT kinoshitaryosuke clinicalimpactofserumsolubleslamf7inmultiplemyeloma AT kuribayashiyasuko clinicalimpactofserumsolubleslamf7inmultiplemyeloma AT onoderaasaka clinicalimpactofserumsolubleslamf7inmultiplemyeloma AT moriyakeiichi clinicalimpactofserumsolubleslamf7inmultiplemyeloma AT tanakajunji clinicalimpactofserumsolubleslamf7inmultiplemyeloma AT tsukuneyutaka clinicalimpactofserumsolubleslamf7inmultiplemyeloma AT komatsunorio clinicalimpactofserumsolubleslamf7inmultiplemyeloma AT inokuchikoiti clinicalimpactofserumsolubleslamf7inmultiplemyeloma AT tamurahideto clinicalimpactofserumsolubleslamf7inmultiplemyeloma |